Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)

Trial Profile

Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs TGR 1202 (Primary) ; Ublituximab (Primary) ; Pembrolizumab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 13 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 13 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
    • 09 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by TG Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top